Mason II Dotaz Zobrazit nápovědu
CIEĽ ŠTÚDIE: Autori prezentujú pooperačné výsledky u 21 pacientov ošetrených v rokoch 1999 až 2008 pre zlomeninu hlavičky radia typu Mason II. Poukazujú na výhody osteosyntézy hlavičky radia pomocou Herbertovej skrutky pri tomto type zlomenín. MATERIÁL: Hodnotili 21 pacientov po operácii zlomeniny hlavičky radia typu Mason II. V súbore bolo 9 mužov a 12 žien. Priemerný vek pacientov bol 41,10 rokov (od 17-60 rokov). Pacientov operovali priemerne do 6 dní od úrazu. Na kontrolu prišli priemerne po 3 rokoch a 8 mesiacoch (1-8 rokov). METÓDY: Retrospektívne hodnotili pacientov pomocou kontrolného funkčného, röntgenologického vyšetrenia, za použitia Mayo Elbow Performance Score (MEPS) [17], skóre Radina a Riseborougha [25|, skóre Broberga a Morreyho [2] v modifikácii podľa Judeta [8], Oxford Elbow skóre (OES) [19] a Disabilities of the Arm, Shoulder and Hand (DASH) Skóre [3]. VÝSLEDKY: Pomocou MEPS dosiahli výborný výsledok u 13 pacientov a dobrý výsledok u 8 pacientov. Pomocou skóre podľa Radina a Riseborougha zistili dobrý výsledok u 13 pacientov, vyhovujúci výsledok u 5 pacientov a zlý výsledok u 3 pacientov. Pomocou skóre podľa Broberga a Morreyho v modifikácii podľa Judeta dosiahli výborný výsledok u 9 pacientov, dobrý výsledok u 9 pacientov a u 3 pacientov vyhovujúci výsledok. Priemerná hodnota DASH bola 4,22 a priemerná hodnota OES dosiahla 44,62 bodov, čo svedčí pre vyhovujúcu funkciu kĺbu. ZÁVER: Na základe retrospektívnej štúdie autori doporučujú využitie Herbertovej skrutky pri liečbe všetkých zlomenín hlavičky radia typu Mason II, kde veľkosť fragmentu umožňuje jej použitie. Za jedno z najväčších pozitív Herbertovej skrutky považujú schopnosť zabezpečiť stabilnú fixáciu zlomeniny a z toho plynúcu možnosť včasnej funkčnej liečby pacientov.
PURPOSE OF THE STUDY: The authors present postsurgical results in 21 patients treated in 1999– 2008 for radial head fractures of Mason II type. They stress advantages of radial head osteosynthesis with Herbert screw in this type of fractures. MATERIAL: They evaluated 21 patients after surgical treatment of radial head fractures of Mason II type. Their set consisted of 9 men and 12 women. Mean age of the patients was 41.10 years (17–60 years). The patients were operated within an average of 6 days after the injury. They underwent postsurgical examination in an average of 3 years and 8 months (1–8 years). METHODS: They evaluated the patients retrospectively by means of functional and X-ray examinations, Mayo Elbow Performance Score (MEPS) [17], Radin and Riseborough score [25|, Broberg and Morrey score [2] in modification according to Judet [8], Oxford Elbow score (OES) [19] and Disabilities of the Arm, Shoulder and Hand (DASH) Score [3]. RESULTS: Using MEPS they achieved excellent results in 13 patients and good results in 8 patients. Using Radin and Riseborough score they achieved good results in 13 patients, satisfactory results in 5 patients and bad results in 3 patients. Using Broberg and Morrey score in modification according to Judet they achieved excellent results in 9 patients, good results in 9 patients and satisfactory results in 3 patients. The mean value of DASH was 4.22 and the mean value of OES was 44.62 points, which manifests satisfactory joint function. CONCLUSIONS: Based on retrospective study the authors recommend use of Herbert screw in treatment of all radial head fractures of Mason II type if size of the fragment enables its use. They consider ability to provide stable fixation of the fracture and possibility of early functional treatment of patients as the greatest positives of the Herbert screw. KEY WORDS: radial head fractures, Mason II, Herbert screw.
- Klíčová slova
- zlomeniny hlavičky radia, Mason II, Herbertova skrutka,
- MeSH
- dospělí MeSH
- fraktury vřetenní kosti chirurgie MeSH
- kostní šrouby statistika a číselné údaje využití MeSH
- lidé středního věku MeSH
- lidé MeSH
- pooperační komplikace MeSH
- retrospektivní studie MeSH
- vnitřní fixace fraktury metody využití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
BACKGROUND: The role of cholesterol homeostasis in neuroaxonal injury in multiple sclerosis is not known. OBJECTIVE: The objective of the study is to investigate the associations of cerebrospinal fluid (CSF) and serum neurofilament light chain levels (CSF-NfL and sNfL, respectively), which are biomarkers of neuroaxonal injury, with cholesterol biomarkers at the clinical onset of multiple sclerosis. METHODS: sNfL, serum cholesterol profile (total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol), serum apolipoprotein (Apo) levels (ApoA-I, ApoA-II, ApoB, and ApoE), and albumin quotient were obtained for 133 patients (63% female, age: 29.9 ± 8.0 years) during the first demyelinating event. CSF-NfL was available for 103 (77%) patients. RESULTS: CSF-NfL and sNfL were negatively associated with serum ApoA-II (P = .005, P < .001) and positively associated with albumin quotient (P < .001, P < .0001). In addition, higher CSF-NfL was associated with lower serum ApoA-I (P = .009) levels and higher sNfL was associated with lower high-density lipoprotein cholesterol (P = .010). In stepwise regression, age (P = .045), serum ApoA-II (P = .022), and albumin quotient (P < .001) were associated with CSF-NfL; albumin quotient (P = .002) and ApoA-II (P = .001) were associated with sNfL. Path analysis identified parallel pathways from ApoA-II (P = .009) and albumin quotient (P < .001) to the sNfL outcome that were mediated by CSF-NfL (P < .001). The associations of CSF-NfL with ApoA-I (P = .014) and ApoA-II (P = .015) and sNfL with ApoA-II (P < .001) remained significant after adjusting for number of contrast-enhancing lesions and T2 lesion volume. CONCLUSION: Lower serum ApoA-II and ApoA-I levels are associated with greater neuroaxonal injury as measured by CSF-NfL.
- MeSH
- apolipoprotein A-I krev MeSH
- apolipoprotein A-II krev MeSH
- dospělí MeSH
- lidé MeSH
- longitudinální studie MeSH
- neurofilamentové proteiny mozkomíšní mok MeSH
- neuroprotektivní látky krev mozkomíšní mok MeSH
- prognóza MeSH
- prospektivní studie MeSH
- roztroušená skleróza krev mozkomíšní mok patologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Retroviral gag proteins, as well as fragments minimally containing the capsid (CA) and nucleocapsid (NC) subunits of Gag, are able to spontaneously assemble into virus-like particles (VLPs). This occurs in mammalian and bacterial cells as well as in in vitro systems. In every circumstance, nucleic acids are incorporated into the forming particles. Here, we took advantage of an in vitro system for the generation of non-enveloped Mason-Pfizer monkey virus (M-PMV) VLPs derived from a self-assembling CA-NC subunit of Gag. These VLPs were modified through N-terminal extension of CA-NC with short oligopeptides that, after the assembly process, were exposed on the surface of VLPs. The employed N-terminal modifications allowed specific interaction with target cells expressing prostate-specific membrane antigen. Using this system, we were able to incorporate selected siRNA into forming VLPs and deliver it into the cytosol of target cells. In comparison with other viral vectors designed for targeted transgene delivery, this M-PMV VLP system represents the lowest risk of generating virus-associated pathology, as the VLPs do not contain any viral coding sequences and are formed in a cell-free system.
- MeSH
- antigeny povrchové metabolismus MeSH
- buněčné linie MeSH
- glutamátkarboxypeptidasa II metabolismus MeSH
- lidé MeSH
- makromolekulární látky metabolismus MeSH
- malá interferující RNA metabolismus MeSH
- Masonův-Pfizerův opičí virus genetika MeSH
- přichycení viru * MeSH
- transdukce genetická * MeSH
- virům podobné částice genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- MeSH
- antagonisté androgenů MeSH
- bisfosfonáty MeSH
- humanizované monoklonální protilátky farmakologie MeSH
- kastrace MeSH
- klinické zkoušky, fáze II jako téma MeSH
- klinické zkoušky, fáze III jako téma MeSH
- kryochirurgie metody MeSH
- kvalita života MeSH
- lidé MeSH
- metastázy nádorů MeSH
- multicentrické studie jako téma MeSH
- nádory prostaty * terapie MeSH
- náklady na léky MeSH
- oligopeptidy farmakologie MeSH
- přežití MeSH
- prognóza MeSH
- prospektivní studie MeSH
- prostata * patofyziologie účinky léků MeSH
- receptory LHRH účinky léků MeSH
- retrospektivní studie MeSH
- riziko MeSH
- testosteron sekrece MeSH
- transrektální ultrazvuk o vysoké intenzitě MeSH
- výběr pacientů MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
We investigated aspirin-prescribing patterns and potential benefits on cardiovascular morbidity and mortality in hemodialysis patients. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: Data included 28,320 randomly selected hemodialysis patients from the Dialysis Outcomes and Practice Patterns Study I and II. PREDICTOR: Aspirin prescription at study baseline. OUTCOMES & MEASUREMENTS: Prescription was investigated by means of logistic regression. All-cause mortality, all-cause hospitalization, cardiac event, myocardial infarction, cerebrovascular (CVA), gastrointestinal bleed, transient ischemic attack, and subdural hematoma were examined. Cox regression examined the risk of mortality and hospitalization. All models accounted for facility clustering and demographics and comorbid conditions. RESULTS: Wide variation was found in aspirin prescription, from 8% in Japan to 41% in Australia and New Zealand. Characteristics significantly associated with increased odds of prescription included coronary artery disease, cerebrovascular disease, diabetes, male sex, nonblack race, peripheral vascular disease, age, hypertension, and absence of gastrointestinal bleeding. Aspirin was associated with decreased risk of stroke in all patients (relative risk [RR], 0.82; P < 0.01) and increased risk of myocardial infarction (RR, 1.21; P = 0.01) and cardiac event (RR, 1.08; P < 0.01) in all patients, with similar results for patients with coronary artery disease. There was no increase in gastrointestinal bleeding. LIMITATIONS: Observational studies are not protected from biases, despite adjustments. There is potential for aspirin use to be underreported because of its availability without prescription. CONCLUSIONS: The hypothesis that prescribing aspirin to hemodialysis patients decreases cardiovascular disease risk is not supported. Aspirin might decrease CVA and appears not to increase hemorrhagic risk. This should be an incentive for randomized controlled trials.
BACKGROUND: The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764) assessed the safety and activity of isatuximab plus atezolizumab (Isa + Atezo), an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with immunotherapy-naive solid tumors: epithelial ovarian cancer (EOC), glioblastoma (GBM), hepatocellular carcinoma (HCC), and squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Phase I assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and the recommended phase II dose (RP2D) of isatuximab 10 mg/kg intravenously (i.v.) every week for 3 weeks followed by once every 3 weeks + atezolizumab 1200 mg i.v. every 3 weeks. Phase II used a Simon's two-stage design to assess the overall response rate or progression-free survival rate at 6 months (GBM cohort). Interim analysis was carried out at 6 months following first dose of the last enrolled patient in each cohort. Pharmacodynamic biomarkers were tested for CD38, PD-L1, tumor-infiltrating immune cells, and FOXP3+ regulatory T cells (Tregs) in the tumor microenvironment (TME). RESULTS: Overall, 107 patients were treated (EOC, n = 18; GBM, n = 33; HCC, n = 27; SCCHN, n = 29). In phase I, Isa + Atezo showed an acceptable safety profile, no dose-limiting toxicities were observed, and RP2D was confirmed. Most patients experienced ≥1 treatment-emergent adverse event (TEAE), with ≤48.5% being grade ≥3. The most frequent TEAE was infusion reactions. The study did not continue to stage 2 based on prespecified targets. Tumor-infiltrating CD38+ immune cells were reduced and almost cleared after treatment. Isa + Atezo did not significantly modulate Tregs or PD-L1 expression in the TME. CONCLUSIONS: Isa + Atezo had acceptable safety and tolerability. Clinical pharmacodynamic evaluation revealed efficient target engagement of isatuximab via treatment-mediated reduction of CD38+ immune cells in the TME. Based on clinical data, CD38 inhibition does not improve responsiveness to PD-L1 blockade in these patients.
- MeSH
- antigeny CD274 metabolismus MeSH
- forkhead transkripční faktory MeSH
- hepatocelulární karcinom * MeSH
- lidé MeSH
- nádorové mikroprostředí MeSH
- nádory jater * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze I MeSH
- klinické zkoušky, fáze II MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Klíčová slova
- Temodal (temozolomidum),
- MeSH
- adjuvantní chemoradioterapie metody MeSH
- analýza přežití MeSH
- celková dávka radioterapie MeSH
- chemoradioterapie metody MeSH
- glioblastom * farmakoterapie patologie radioterapie MeSH
- inhibitory enzymů MeSH
- Kaplanův-Meierův odhad MeSH
- konformní radioterapie MeSH
- lidé MeSH
- O(6)-methylguanin-DNA-methyltransferasa antagonisté a inhibitory MeSH
- temozolomid aplikace a dávkování MeSH
- Check Tag
- lidé MeSH
Annales d'endocrinologie, ISSN 0003-4266 vol. 66, cahier 2, Avril 2005
101 s. : il. ; 27 cm
- MeSH
- diabetes mellitus 2. typu komplikace farmakoterapie MeSH
- hodnocení léčiv MeSH
- kardiovaskulární nemoci MeSH
- metabolický syndrom MeSH
- thiazolidindiony farmakologie terapeutické užití MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Farmacie. Farmakologie
- NLK Obory
- endokrinologie
- vnitřní lékařství
- diabetologie
- farmacie a farmakologie
Cieľom práce bolo porovnať výsledok rôzne volenej chirurgickej liečby pri rôznych typoch zlomenín hlavice rádia versus totálna exstirpácia hlavice rádia. Kontrolné vyšetrenie bolo realizo-vané u 42 pacientov 9-12 mesiacov od operačného ošetrenia. Výsledky boli analyzované použitím klasifikácie Wesley et al. [1983]. Najlepšie výsledky boli dosiahnuté pri Mason II type zlomenín, nasledoval typ III a typ IV zlomenín. Po-rovnaním rôznych typov operácií najlepší výsledok bol dosiahnutý pri osteosyntéze skrutkami pri Mason II a III type zlomenín, nasledovala extrakorporálna osteosutúra (hlavica rádia vložená ako spacer). Zlé výsledky boli po totálnej ex-stirpácii hlavice rádia. Menej kominutívna zlomenina hlavice rádia má lepšie operačné výsledky. Osteosyntézu skrutkami treba preferovať, ak je technicky možná. Totálnu exstirpáciu hlavice rádia považujeme za kontraindikovanú.
The purpose of this study was to compare the outcome of various surgical options exercised in the management of different types of radial head fractures versus total exstirpation of radial head. 42 patients were reexamined, with an average follow-up period of 9-12 months after surgical treatment. The results were analysed according to the classification of Wesley et al. [1983]. The best results were obtained in Mason type II fractures, followed by type III and type IV fractures. Com-paring different operations, the best outcome was observed with screw fixation of Mason type II and type III fractures, followed by extracorporal osteosutures (radial head to insert as spacer). Poor results were obtained after exstirpation of the radial head. The less comminution a radial head fracture appears, the better is the outcome. Screw fixation is to be preferred, if technically possible. Total exstirpation of radial head is contraindicated.
- MeSH
- fixace fraktur metody statistika a číselné údaje MeSH
- fraktury vřetenní kosti chirurgie rehabilitace MeSH
- hojení fraktur MeSH
- lidé středního věku MeSH
- lidé MeSH
- ortopedické výkony metody statistika a číselné údaje MeSH
- senioři statistika a číselné údaje MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři statistika a číselné údaje MeSH
- ženské pohlaví MeSH
